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Detection of methicillin-resistant Staphylococcus aureus
(MRSA) in specimens from various body sites: performance
characteristics of the BD GeneOhm MRSA assay, the Xpert
MRSA assay, and broth-enriched culture in an area with a low
prevalence of MRSA infections
Abstract
Universal surveillance upon patient admission is important in reducing the transmission of
methicillin-resistant Staphylococcus aureus (MRSA) and associated disease in hospitals. High costs for
the health care system in conjunction with MRSA have promoted the development of rapid screening
methods to detect MRSA carriers. This study compared two real-time PCR methods, the BD GeneOhm
MRSA assay (BDGO) and the Xpert MRSA assay, with broth-enriched culture to define their
performance characteristics and rapidity in an area with low MRSA prevalence. In total, 414 swabs from
the nose and 389 swabs from the groin from 425 patients were tested. Of those 425 patients, 378 had
swabs from both the nose and groin in parallel. Two hundred thirty-one and 194 patients were randomly
assigned to the BDGO group and the Xpert MRSA group, respectively. In general, sensitivity,
specificity, and negative predictive value (NPV) were high for the BDGO (100%, 98.5%, and 100%,
respectively) and the Xpert MRSA (100%, 98.2%, and 100%, respectively), irrespective of whether or
not nasal and inguinal specimens were considered alone or combined. In contrast, the positive predictive
value (PPV) was lower: before the resolution of discrepant results, the PPVs for nasal and inguinal
specimens alone and combined were 87.5%, 86.7%, and 82.4% for the BDGO and 91.7%, 66.7%, and
92.9% for the Xpert MRSA, respectively. After the resolution of discrepant results, PPVs were 93.8%,
93.3% and 94.1% for the BDGO and 91.7%, 88.9% and 92.9% for the Xpert MRSA, respectively. With
the BDGO, 4 of 16 carriers were each identified by nasal or inguinal swabs alone, whereas in the Xpert
MRSA group, 4 of 13 carriers were exclusively identified by nasal swabs and 2 of 13 were identified by
inguinal swabs alone. Both PCR methods showed no significant difference in the number of discrepant
results (odds ratio, 0.70 [P = 0.789]), but specimens from wounds and other body sites (axilla, vagina,
and throat) produced discrepancies more often than nasal and groin specimens (odds ratios, 4.724 [P =
0.058] and 12.163 [P < 0.001], respectively). The facts that no false-negative PCR results were detected
and increased PPVs were found after the resolution of discrepant results point to PCR as the actual gold
standard. Since both sensitivity and NPV were exceptionally high for PCR, backup cultures may,
therefore, be unnecessary in an area with low prevalence and with a preemptive isolation strategy but
may still be useful for PCR-positive specimens because of the lower PPV for both methods and the
possibility of susceptibility testing. The median time for analysis, including extraction, hands-on time,
and actual PCR was 2 h 20 min for the Xpert MRSA versus 5 h 40 min for the BDGO. Concerning
reporting time, including administration and specimen collection, the Xpert MRSA was faster than the
BDGO (7 h 50 min versus 17 h).
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ABSTRACT 25 
Universal surveillance upon patient admission is important in reducing transmission of 26 
methicillin-resistant Staphylococcus aureus (MRSA) and associated disease in hospitals. High 27 
cost for the health care system in conjunction with MRSA has promoted the development of 28 
rapid screening methods to detect MRSA carriers. This study aimed at comparing two real-29 
time PCR methods, the BD GeneOhm™ MRSA assay (BDGO) and the Xpert™ MRSA 30 
assay, with broth-enriched culture to define their performance characteristics and rapidity in a 31 
low-prevalence area of MRSA. In total, 414 swabs from nose and 389 swabs from groin were 32 
tested from 425 patients. Of those 425 patients 378 had swabs from both nose and groin in 33 
parallel. 231 and 194 patients were randomly assigned to the BDGO group and Xpert™ 34 
MRSA group, respectively. In general, sensitivity, specificity and negative predictive value 35 
(NPV) were high for the BDGO (100%, 98.5% and 100%, respectively) and the Xpert™ 36 
MRSA (100%, 98.2% and 100%, respectively), irrespective of whether or not nasal and 37 
inguinal specimens were considered alone or combined. In contrast, the positive predictive 38 
value (PPV) was lower: Before resolution of discrepant results the PPV for nasal and inguinal 39 
specimens alone and combined was 87.5%, 86.7 and 82.4% for the BDGO and 91.7, 66.7 and 40 
92.9 for the Xpert MRSATM, respectively. After resolution of discrepant results the PPV was 41 
93.8%, 93.3 and 94.1% for the BDGO and 91.7, 88.9 and 92.9 for the Xpert MRSATM, 42 
respectively. With the BDGO 4 of 16 carriers were each identified by nasal or inguinal swabs 43 
alone, whereas in the Xpert MRSATM group 4 of 13 carriers were exclusively identified by 44 
nasal swabs and 2 of 13 were identified by inguinal swabs alone. Both PCR methods showed 45 
no significant difference in the number of discrepant results (Odds ratio 0.70, p = 0.789), but 46 
specimens from wounds and other body sites (axilla, vagina, throat) produced discrepancies 47 
more often if compared to nasal and groin specimens (Odds ratios 4.724, p = 0.058, and 48 
12.163, p < 0.001, respectively). The fact that no false-negative PCR results were detected 49 
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and an increased PPV after resolution of discrepant results point to PCR as the actual gold 50 
standard. Since both sensitivity and NPV were exceptionally high for PCR, backup cultures 51 
may, therefore, be unnecessary in a low-prevalence area with a pre-emptive isolation strategy, 52 
but may still be useful for PCR-positive specimens because of the lower PPV for both 53 
methods and the possibility of susceptibility testing. Median time for analysis including 54 
extraction, hands-on time and actual PCR was 2 h 20 min for the Xpert MRSA versus 5 h 40 55 
min for the BDGO, respectively. Concerning reporting time including administration and 56 
specimen collection the Xpert™ MRSA was faster than the BDGO (7 h 50 min versus 17 h).  57 
 58 
INTRODUCTION 59 
Methicillin-resistant Staphylococcus aureus (MRSA) strains have become a major concern 60 
for health care systems. Prevention of MRSA spreading has, therefore, become a main goal in 61 
the past decade, and active screening programs have been established worldwide (4, 26). If 62 
compared to infections caused by methicillin-susceptible S. aureus (MSSA) the organism 63 
causes severe infections with increased morbidity, mortality, and prolonged hospitalization (9, 64 
17). Contrary to countries facing a high prevalence of MRSA like the USA and Japan, 65 
prevalence in Switzerland has remained low to date (5, 13, 21, 31). In most parts of our 66 
country prevalence rates between 4 and 7% are observed (19). Apart from spreading in the 67 
hospital environment MRSA carriage in our community as well as other countries seems to be 68 
more prevalent than previously assumed (30, 31, 36). 69 
To facilitate rapid detection of colonized patients real-time PCR assays have been 70 
developed. The first method to directly detect MRSA from clinical specimens was developed 71 
by Huletsky et al. (20). The principle of this method is used in two commercially available 72 
tests, i) the BD-GeneOhm-MRSA assay (BDGO) (BD-GeneOhm, San Diego, CA), and ii) the 73 
Xpert™ MRSA assay (Cepheid, Inc., Sunnyvale, CA).  74 
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Recent studies have shown that universal admission surveillance for MRSA was associated 75 
with a reduction in MRSA disease (18, 27). Likewise, Cunningham et al. have reported a 76 
reduction in MRSA transmissions in a critical care unit. The authors attributed these findings, 77 
at least partially, to the availability of rapid PCR screening tests, apart from other measures 78 
like improved hygiene measures (10). PCR screening methods are cost-efficient, especially in 79 
a low-prevalence area where high-risk patients are subjected to pre-emptive contact isolation 80 
(6). Our facility is a 1,000-bed tertiary care teaching hospital with a known low prevalence 81 
(< 5%) for MRSA colonization of patients, and follows a surveillance policy similar to that of 82 
the University Hospital of Berne, Switzerland (6). As reported in other studies this means pre-83 
emptive isolation on admission of all patients who i) came from or had travelled to countries 84 
with known high prevalence rates for MRSA; ii) were transferred from long-term care 85 
facilities; iii) were transferred from another health care facility; iv) were hospitalized within 86 
the previous 6 months; and/or v) had a history of MRSA colonization or infection (6, 8, 23). 87 
As soon as PCR is negative for MRSA patient isolation is stopped. Under these 88 
circumstances, a rapid screening method with a high NPV is desirable, because the bulk of 89 
cost emerge mainly from non-colonized patients being unnecessarily isolated. In this study, 90 
we aimed at comparing two real-time PCR methods, the BDGO and Xpert™ MRSA assays, 91 
with broth-enriched culture to assess their performance characteristics and rapidity in a low-92 
prevalence area for MRSA.  93 
 94 
MATERIALS AND METHODS 95 
Patients and Clinical Specimens. This study was conducted prospectively over a period of 96 
12 months at the Luzerner Kantonsspital (LUKS) from August 2007 to August 2008. Swabs 97 
from nose, groin, wound, axilla, vagina, and throat were collected on admission according to 98 
the LUKS policy for MRSA screening for patients with a high risk for MRSA carriage. High-99 
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risk patients were individuals who i) came from or had travelled to countries with known high 100 
prevalence rates for MRSA; ii) were transferred from long-term care facilities; iii) were 101 
transferred from another health care facility; iv) were hospitalized within the previous 6 102 
months; and/or v) had a history of MRSA colonization or infection. Double-swabs were 103 
transported in Copan Transystem Liquid Stuart (Copan Italia S.p.A., Brescia, Italy) and stored 104 
at room temperature. If further processing of the swabs was not possible on the same day, 105 
swabs were stored overnight at 4° C. Patient samples were then randomly assigned to be 106 
tested with either the BDGO or the Xpert™ MRSA assay. 107 
BD-GeneOhm-MRSA™ assay (BDGO). Swabs were transferred to the sample reagent 108 
buffer and processed for cell lysis and DNA extraction according to the manufacturer’s 109 
recommendations. Lysed specimen (2.8 µl) was added to the PCR tubes containing 25 µl of 110 
the reconstituted master mix. PCR was performed with the Smart Cycler® II instrument 111 
(Cepheid, Sunnyvale, CA). Positive and negative controls were included in each run. In case 112 
of inhibition the sample was briefly frozen to remove inhibitors and the run repeated. If a 113 
sample was still inhibited after freezing-thawing the lysed specimen was diluted 1:20 with 114 
sample reagent buffer and the run repeated. The BDGO is both FDA approved in the US and 115 
CE approved in Europe for nasal specimens exclusively. Since there are instructions of the 116 
manufacturer for nasal swabs only, specimens from body sites other than the nares were 117 
treated as were the nasal ones. 118 
Xpert™ MRSA assay. According to the instructions of the manufacturer swabs were 119 
transferred into extraction buffer vials and mixed to remove bacteria from the swab. Again, 120 
nasal specimens only are FDA and CE approved. Specimens from body sites other than the 121 
nares were treated the same way as nasal ones.  122 
Detection of MRSA by culture. In parallel to PCR, the second part of the double swab was 123 
transferred into enrichment broth (1 ml; Tryptic Soy Broth [Becton Dickinson, Franklin 124 
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Lakes, NJ] supplemented with 7.5% NaCl) and incubated for 24 h in ambient air at 35° C. 125 
Subcultures were done on chromogenic agar medium (Chrom IDTM MRSA Agar, bioMérieux, 126 
Marcy l'Etoile/France) at 35° C in ambient air. Plates were read after 24 and 48 h of 127 
incubation, respectively. Blue colonies were tested by the Staphaurex Plus test (Remel Europe 128 
Ltd., Dartford, Kent/UK). Presence of MRSA was confirmed by the Vitek 2 System 129 
(bioMérieux; GP colorimetric identification card; software version 04.03). Susceptibility 130 
testing for confirmation of methicillin resistance was done by the disk diffusion method with 131 
30-µg cefoxitin disks (bioMérieux) according to the guidelines of the Clinical Laboratory 132 
Standards Institute (CLSI) (7). 133 
Calculation of inhibition rates. Initial inhibition rates were recorded for both test systems. 134 
For the BDGO inhibition rates were recalculated after freezing-thawing and after freezing-135 
thawing/diluting the sample 1:20 with sample reagent buffer, respectively. For the Xpert™ 136 
MRSA assay repeating a test was not possible. 137 
Resolution of discrepant results. Specimens showing discrepant results for the BDGO and 138 
Xpert MRSA assays and culture were further analyzed. In case of PCR-positive but culture-139 
negative results from one body site and concordantly positive results of specimens from 140 
another body site of the same patient at the same time, PCR results were regarded as true-141 
positives (TP).  142 
Data analysis of PCR results.  Specificity, PPV, and NPV were calculated for the BDGO 143 
and the Xpert™ MRSA assay compared to culture as the gold standard before and after 144 
resolution of discrepant results. Confidence intervals were calculated according to the 145 
Wilson’s method (1), odds ratios were calculated for the frequency of discrepant results with 146 
culture comparing both PCR based methods in general as well as different types of specimens 147 
with nasal specimens as the Food and drugs administration (FDA) approved reference by 148 
logistic regression adjusted for clustering. 149 
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Calculation of turnaround times. Transport time (collecting to arrival at the laboratory) and 150 
laboratory turnaround time (arrival of specimen to reporting of either PCR or culture results) 151 
were recorded electronically in hours and minutes for each specimen and the median was 152 
calculated. Reporting time (sampling to reporting of results) was calculated as the sum of 153 
transport and laboratory turnover times. 154 
Software. All calculations were done with the MS Excel Software (Microsoft, Redmond, 155 
WA) and the Stata software (StataCorp LP, College Station, TX). Results of the analysis with 156 
p-values < 5% were considered statistically significant. 157 
 158 
RESULTS 159 
In total, 414 swabs from nose and 389 swabs from groin were tested from 425 patients. Of 160 
those 425 patients 378 had swabs from both nose and groin in parallel. 231 and 194 patients 161 
were randomly assigned to the BDGO group and Xpert™ MRSA group, respectively.   162 
In the BDGO group 8 of 13 initially inhibited specimens could eventually be included in 163 
the data analysis, because results became available after a freezing/thawing step. The 164 
remaining 5 specimens could be included after a freezing/thawing step plus a 1:20 dilution 165 
step of the extracted DNA. Specimens from 7 of 194 patients in the Xpert™ MRSA group 166 
were excluded from the study due to persistent PCR inhibition. 167 
Initial inhibition rates with swabs from nose and groin were comparably low in the BDGO 168 
group (1.7% and 1.3%, respectively) and the Xpert™ MRSA group (1.6% and 1.7%, 169 
respectively). For wound specimens the Xpert™ MRSA showed distinctly lower initial 170 
inhibition rates than the BDGO (0 and 6.2%, respectively). Repeat PCRs were possible with 171 
the BDGO samples and the inhibition rate dropped to 0 after a freezing/thawing step, 172 
followed by a 1:20 dilution step of the lysate.  173 
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Performance characteristics of the BDGO and Xpert MRSATM were calculated for each 174 
specimen type separately as well as for nose and groin specimens combined before and after 175 
resolution of discrepant results (Table 2) using broth-enriched culture as the gold standard 176 
(Table 1). No significant differences in the performance of the two PCR methods were 177 
observed. Sensitivity, specificity and negative predictive value (NPV) of the BDGO was high 178 
already before resolution of discrepant results (100%, 98.5% and 100%, respectively) 179 
irrespective of body sites considered alone or combined. The same was true for the Xpert 180 
MRSATM MRSA with a sensitivity, specificity and NPV of 100%, 98.2% and 100%, 181 
respectively. After resolution of discrepancies sensitivity, specificity and negative predictive 182 
value marginally changed to 100%, 99.5%, and 100% for the BDGO and 100%, 99.4%, and 183 
100% for the Xpert MRSATM MRSA, respectively. In contrast, the positive predictive value 184 
(PPV) was lower: Before resolution of discrepant results the PPV for nasal specimens was 185 
87.5% and 91.7% for the BDGO and Xpert MRSATM, respectively. After resolution of 186 
discrepant results the PPV for nasal specimens rose to 93.8% for the BDGO and remained 187 
91.7% for the Xpert MRSATM. For specimens from the groin the PPV was only 86.7% and 188 
66.7% before resolution of discrepant results and rose to 93.3% and 88.9% after resolution of 189 
discrepant results for the BDGO and Xpert MRSATM, respectively. Combining specimens 190 
from nose and groin resulted in a PPV of 82.4% and 92.9% before resolution of discrepancies 191 
and 94.1% and 92.9% after resolution of discrepancies for the BDGO and Xpert MRSATM, 192 
respectively. 193 
Taking swabs from nose and groin resulted in a higher detection rate of MRSA carriers: In 194 
the BDGO group with specimens from nose and groin 4 of 16 carriers were each identified by 195 
nasal or inguinal swabs alone, whereas 8 carriers showed positive PCR results for both body 196 
sites. In the Xpert MRSATM group with specimens from nose and groin 4 of 13 carriers were 197 
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exclusively identified by nasal swabs and 2 of 13 were identified by inguinal swabs alone, 198 
whereas 7 carriers showed positive PCR results for both body sites. 199 
Additionally, the probability of producing discrepant results was analyzed by logistic 200 
regression adjusted for clustering to compare both PCR methods as well as different body 201 
sites. If both PCR tests were compared independent of the body site there was no difference in 202 
the probability of producing discrepant results with culture (Odds ratio 0.70, p = 0.789, 95%). 203 
To compare the body sites nasal specimens were chosen as the comparator as they are widely 204 
accepted and approved by the FDA. In addition to specimens from the groin (n = 389) other 205 
body sites were included into the analysis (wounds [n = 99], axilla [n = 24], throat [n = 11], 206 
and vagina [n = 3]). If body sites were compared regarding the probability of discrepant 207 
results (in our case for PCR-positive and culture-negative results [FP] only) significant 208 
differences were detected independent of the PCR method: Specimens from groin only tended 209 
to produce discrepant results more often compared to nasal specimens (Odds ratio 1.09, p = 210 
0.001), while specimens from wounds and various other body sites (axilla, vagina, throat) 211 
exhibited a distinct higher probability of discrepant results (Odds ratios 4.724, p = 0.058, and 212 
12.163, p < 0.001, respectively). 213 
Turnaround times for the BDGO and Xpert™ MRSA are shown in Table 3. Transport time 214 
was the same for both assays, but reporting times of the PCR methods differed: the Xpert™ 215 
MRSA revealed a reporting time of 7 h 50 min and thus, provided results 9 h and 10 min 216 
earlier than the BDGO to the clinicians.  217 
 218 
DISCUSSION 219 
Several recent studies have aimed at comparing the BDGO and Xpert™ MRSA assays in 220 
high-prevalence countries (22, 28, 33-35). In our study, not only did we aim at comparing 221 
classical performance parameters like sensitivity, specificity, PPV, and NPV in a low-222 
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prevalence area, but also analyzed the likelihood of discrepant PCR and culture results for 223 
specimens from body sites other than the nares. In addition, we assessed the rapidity by which 224 
the respective results became available.  225 
Both PCR assays had comparable sensitivities, specificities, PPVs, and NPVs, similar to 226 
what has been observed by others (2, 11, 22, 25, 32, 34). Notably, the sensitivity of the 227 
BDGO in this study was found to be higher (100% vs. 84.3%) than in our previous study (23). 228 
This may possibly be attributed to the use of Amies gel agar in the previous study instead of 229 
liquid Stuart’s medium as used in the current one. Use of an agar-based medium may 230 
compromize the elution process of staphylococcal organisms. 231 
Most recently, Kelly et al. (22) reported that sampling more than one single body site with 232 
pooled swabs from nose and groin resulted in a higher detection rate of colonization by PCR 233 
screening assays in a high-prevalence area (2, 14, 22, 24), while sensitivity and PPV (ranging 234 
from 84.8% to 87% and from 76.5 to 80%, respectively) were relatively low. Our results 235 
support those findings inasmuch as the detection rate of MRSA carriers was increased by 25% 236 
(4 of 16 carriers) and 15.4% (2 of 13 carriers) with the BDGO and Xpert MRSATM, 237 
respectively, if swabs from groin were added to those from the nares. Sensitivity, specificity, 238 
PPV and NPV of combined swabs equalled the performance values of swabs from a single 239 
body site. Thus, an advantage of pooling specimens from nose and groin are lower cost for 240 
MRSA screenings along with an even enhanced detection rate of MRSA carriers. However, 241 
for specific decolonization procedures additional testing will be necessary to determine the 242 
sites actually colonized relativizing cost savings from pooling. 243 
As pointed out by Conterno et al. screening patients by PCR was more costly than 244 
screening them with cultural methods despite an extended period of isolation associated with 245 
culture (8). However, 37% of cost could be attributed to the high rate (41.4%) of patients 246 
isolated because of false-positive results that resulted from a low PPV (65%) of the used IDI-247 
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MRSA assay (now BDGO). On the one hand, PCR-positive, culture-negative results may be 248 
attributed to high colonization rates, e.g. in wounds infected with MSSA containing SCCmec-249 
like elements without a functional mecA gene which are inserted in the same integration site 250 
as SCCmec and reportedly may result in true false-positive PCR results (12, 15), or, on the 251 
other hand, lower colonization rates of other body sites below the detection limit of culture 252 
(28, 29). For one single discrepant result with the Xpert MRSATM (Table 2, patient 4) we 253 
found no possible explanation: Neither could MRSA be detected in other specimens of the 254 
same patient (pointing to an actually true-positive PCR result) nor could MSSA be cultured 255 
from this specimen (pointing to a true false-positive PCR result). Interestingly, 256 
Staphylococcus sciuri was isolated from culture and identified by biochemical and 16S rRNA 257 
gene homology analysis. Hence, PCR was considered false-positive after resolution of 258 
discrepancies. The reason for the positive PCR result remains unclear. Work is in progress to 259 
further characterize this strain. However, S. sciuri is a rarely isolated species in humans and 260 
may bias our results as this specimen was the only false-positive after resolution of 261 
discrepancies with the Xpert MRSATM. Thus, the actual PPV of the Xpert MRSATM in routine 262 
use may even be higher than reported in this study. Results of Wolk et al. (34) for nasal 263 
specimens parallel those of our study using various specimen types. This study and our own 264 
results (no false-negative PCRs, sensitivity of 100%) suggest that the low PPV of PCR assays 265 
may result from the higher sensitivity of PCR assays compared to culture, i.e., PCR is the 266 
likely new gold standard. Our results support those findings inasmuch as 3 of 7 specimens 267 
with PCR-positive culture-negative results went along with positive parallel specimens of the 268 
same patient at the same time, pointing to true-positive PCRs and false-negative cultures 269 
which resulted in an increased PPV (Tables 1 and 2). Furthermore, our data show that 270 
discrepant results for both PCR methods – exclusively FP - occurred significantly more 271 
frequent with swabs from body sites other than the nares and groin, and, therefore, contribute 272 
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to a low PPV. This may be due to lower MRSA colonization rates and, therefore, lower pre-273 
test probability of sites like throat, axilla or vagina compared to the nares (3, 24). Although it 274 
has been recommended to include at least throat specimens for optimal sensitivity our results 275 
indicate that a sensitivity of 100% can be achieved with nasal and inguinal swabs alone (24). 276 
Thus, testing of body sites other than the nares and groin may be dispensable.  277 
Another disadvantage of swabs from body sites other than the nares and groin may be the 278 
higher inhibition rates (1 of 17 swabs and 2 of 22 swabs from other body sites compared to 279 
only 7 of 414 and 6 of 389 for nose and groin swabs for BDGO and Xpert MRSA, 280 
respectively). With specimens from wounds 4 of 65 invalid results were observed with the 281 
BDGO, while with the Xpert™ MRSA none were seen (0 of 34). The number of finally 282 
invalid results due to inhibition for nose and groin specimens was comparably low for both 283 
PCR assays (1.3 to 1.7% and 1.5 to 1.6% for the BDGO and Xpert™ MRSA, respectively). 284 
For the nose and groin swabs analyzed by the BDGO this is well in line with previous reports 285 
(2, 11, 23, 32). Initial inhibition rates of the BDGO can be reduced by a freezing/thawing step 286 
of the DNA extract (12, 22, 37) or be even completely overcome by an additional dilution 287 
step (23, 37). If, however, persistent PCR inhibition is observed for a specimen it seems 288 
reasonable to do cultures and keep the patient isolated until results become available. In the 289 
case of the Xpert™ MRSA our inhibition/invalid rates are far below the values generally 290 
observed, ranging from 4% (28) for nasal swabs up to 20.9% (22) for nose and groin swabs 291 
combined. These high rates may be due to the formation of crystals in the cartridges (22). 292 
Therefore, prewarming of the reagents prior to repeating the test has been suggested, a 293 
strategy which, however, will increase cost (22). Since we have stored the reagents at 4°C and 294 
did not pre-warm them prior to use, the reason for our lower inhibition rates remains 295 
unexplained.  296 
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In addition to the classical performance characteristics a short reporting time for MRSA 297 
detection is crucial to reduce both rate of nosocomial MRSA transmission and number of 298 
patient isolation days (4, 16, 26). Primarily, reporting time depends on turnaround time in the 299 
laboratory, including i) collection time for the specimens in the laboratory to use the PCR 300 
mastermix to its full capacity (for the BDGO only); ii) preanalytic steps; and iii) the time 301 
needed to perform the assay. The BDGO is available for batched, single-use mastermix vials 302 
for as many as 6 specimens plus two controls. In this case collection time in the laboratory is 303 
an important parameter. If used in a hospital with a low prevalence of MRSA carriers there 304 
will be a limited number of screening tests. For financial reasons laboratories will try to 305 
accumulate specimens up to 6 tests before performing the assay. As a consequence, results 306 
may be delayed. Conversely, the Xpert™ MRSA cartridges may be used for one single 307 
specimen at any time, and, therefore, such limitations do not apply for this method.  308 
 In contrast to the fully automated GeneXpert® system another drawback of the BDGO 309 
affecting rapid availability of results is the higher complexity of the system due to the manual 310 
DNA extraction procedure. This will considerably increase the overall time for analysis (in 311 
our study 2 h 20 min for the Xpert MRSA versus 5 h 40 min for the BDGO, respectively). 312 
Our data, however, represent the situation in a low-prevalence area with low numbers of 313 
MRSA screening tests per day. As a consequence, this has considerably increased reporting 314 
time for the BDGO. Reporting time may decrease in high-prevalence areas where screening 315 
tests are performed more frequent, i.e., full BDGO batches are more rapidly achieved.  316 
Altogether, reporting time for results by the Xpert™ MRSA in our setting was 9 hours 317 
shorter than for results generated by the BDGO. Since performance characteristics of both 318 
PCR assays were well comparable the Xpert™ MRSA may outplay the BDGO because of 319 
rapidity and associated cost savings for the hospitals at least if a pre-emptive isolation strategy 320 
is applied. In contrary, if considered per specimen Xpert™ MRSA disposables are more 321 
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expensive compared to the BDGO mastermix used to its full capacity. This holds, in 322 
particular, true for high-prevalence areas for MRSA where large numbers of screening tests 323 
are performed and, as a consequence, the BDGO mastermix will regularly be used up which 324 
results in lower laboratory cost.  325 
From our study there are six major conclusions: (1) both PCR methods performed equally 326 
well regarding sensitivity, specificity, PPV, and NPV as well as the probability of producing 327 
discrepant results compared to culture. (2) Combining swabs from nose and groin increases 328 
the detection rate of MRSA carriers. (3) Taking swabs from body sites other than nares and 329 
groin may not be advisable because of higher inhibition rates and a significantly increased 330 
likelihood of discrepant results. (4) The NPV was exceptionally high (100%) for both PCR 331 
methods demonstrating that back up cultures are unnecessary if PCR is negative. For PCR-332 
positive specimens back up cultures may, however, be useful because of the low PPV even 333 
after resolution of discrepancies. (5) The low PPV of both PCR methods might be due to PCR 334 
rather than culture being the actual gold standard. Culture in all likelihood produces false-335 
negative results and, therefore, is not a true gold standard. (6) Concerning rapid availability of 336 
PCR results the Xpert™ MRSA was superior to the BDGO. 337 
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TABLE 1: Performance parameters of the BD GeneOhm (BDGO) and Xpert MRSA assays and culture 488 
Origin of specimen/Method N TP FP TN FN Sensitivity % (95% CI) 
Specificity %  
(95% CI) 
PPV % 
(95% CI) 
NPV % 
(95% CI) 
Values before resolution              
 
             
Nose                   
BDGO 228 14 2 212 0 100 (78.5-100) 99.1 (96.7-99.7) 87.5 (64.0-96.5) 100 (98.2-100) 
Xpert MRSA 186 11 1 174 0 100 (74.1-100) 99.4 (96.8-99.9) 91.7 (64.6-98.5) 100 (97.8-100) 
               
Groin               
BDGO 213 13 2 198 0 100 (77.2-100) 99.0 (96.4-99.7) 86.7 (62.1-96.3) 100 (98.1-100) 
Xpert MRSA 176 6 3 167 0 100 (61.0-100) 98.2 (94.9-99.4) 66.7 (35.4-87.9) 100 (97.8-100) 
               
Nose and groin combined               
BDGO 210 14 3 193 0 100 (78.5-100) 98.5 (95.6-99.5) 82.4 (59.0-93.8) 100 (98.0-100) 
Xpert MRSA 168 13 1 154 0 100 (77.2-100) 99.4 (96.4-99.9) 92.9 (68.5-98.7) 100 (97.6-100) 
              
Values after resolution              
 
             
Nose                   
BDGO 228 15 1 212 0 100 (79.6-100) 100 (97.4-99.9) 93.8 (71.7-98.9) 100 (98.2-100) 
Xpert MRSA 186 11 1 174 0 100 (74.1-100) 99.4 (96.8-99.9) 91.7 (64.6-98.5) 100 (97.8-100) 
               
Groin               
BDGO 213 14 1 198 0 100 (78.5-100) 99.5 (97.2-99.9) 93.3 (70.2-98.8) 100 (98.1-100) 
Xpert MRSA 176 8 1 167 0 100 (67.6-100) 99.4 (96.7-99.9) 88.9 (56.5-98.0) 100 (97.8-100) 
               
Nose and groin combined               
BDGO 210 16 1 193 0 100 (80.6-100) 99.5 (97.1-99.9) 94.1 (73.0-99.0) 100 (98.0-100) 
Xpert MRSA 168 13 1 154 0 100 (77.2-100) 99.4 (96.4-99.9) 92.9 (68.5-98.7) 100 (97.6-100) 
Values were calculated before and after resolution of discrepancies for specimens from nose and groin alone and 489 
combined with corresponding 95% confidence intervals (CI). TP, true positive; TN, true negative; FP, false 490 
positive; FN, false negative; PPV, positive predictive value; NPV, negative predictive value. 491 
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TABLE 2: Analysis of discrepant results of PCR based methods and culture 492 
MSSA, Methicillin susceptible Staphylococcus aureus; CoNS, coagulase negative staphylococci; TP, true positive; TN, true negative; FP, false 493 
positive; FN, false negative.494 
PCR 
Method Patient 
Origins of 
specimens 
 
Result, further analyses, and actions 
 
Organisms 
cultured 
Rating of PCR result 
before resolution 
Rating of PCR result 
after resolution 
FP FP 1 nose inguina MRSA not detected in other specimens of the same patient 
CoNS 
MSSA FP FP 
2 inguina MRSA confirmed in other specimens of same patient none FP TP 
BDGO 
3 nose MRSA confirmed in other specimens of same patient CoNS FP TP 
 
 
     
FP FP 4 nose inguina MRSA not detected in other specimens of the same patient S. sciuri FP FP 
Xpert 
MRSA 
5 inguina MRSA confirmed in other specimens of same patient CoNS FP TP 
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TABLE 3: Median times for sample processing (in hours and minutes) 495 
 Time for Transport Time for Collectiona Time for Analysisb Time to Reporting 
BDGO 4 h 25 min 6 h 55 min 5 h 40 min 17 h 00 min 
Xpert MRSA 4 h 25 min 1 h 05 min 2 h 20 min 7 h 50 min 
Culture 4 h 25 min directly inoculated 54 h 30 min 68 h 50 min 
 496 
Transport time (collecting to arrival at the laboratory) and laboratory turnaround time (arrival to reporting of 497 
either PCR or culture results), the latter one being divided into time for specimen collection and time for 498 
running the assay. Reporting time (sampling to reporting of results) was calculated as the sum of transport and 499 
laboratory turnaround times. a) Collection includes administration and collection of specimens to utilize the 500 
mastermix to full capacity (BDGO only) b) Analysis includes DNA extraction and PCR 501 
